SCHEMBL25100142

SCHEMBL25100142

CC(=O)CC(C(=O)NCCN(C)C)N(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
PKM P14618 1/20 0.38
DNM1 Q05193 1/20 0.38
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
PRMT3 O60678 1/20 0.35
CARM1 Q86X55 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
PRMT1 Q99873 1/20 0.35
PRMT8 Q9NR22 1/20 0.35
USP2 O75604 2/20 0.35
TSHR P16473 1/20 0.35
PAOX Q6QHF9 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19115849 0.86 ALDH1A1 (0.36) ALDH1A1KDM4EPKMDNM1CA1
SCHEMBL19116205 0.86 ALDH1A1 (0.36) ALDH1A1KDM4EPKMDNM1CA1
SCHEMBL25100347 0.86 ALDH1A1 (0.36) ALDH1A1KDM4EPKMDNM1CA1
SCHEMBL21861807 0.85 PAOX (0.36) ALDH1A1KDM4EPKMDNM1CA1
SCHEMBL26361221 0.83 ALDH1A1 (0.35) ALDH1A1KDM4EPKMDNM1CA1
SCHEMBL26361026 0.83 ALDH1A1 (0.35) ALDH1A1KDM4EPKMDNM1CA1
SCHEMBL19116139 0.82 DNM1 (0.36) ALDH1A1KDM4EPKMDNM1CA1
SCHEMBL19115711 0.82 DNM1 (0.36) ALDH1A1KDM4EPKMDNM1CA1
SCHEMBL20026373 0.82 ALDH1A1 (0.36) ALDH1A1KDM4EPKMDNM1CA1
SCHEMBL19116312 0.82 ALDH1A1 (0.36) ALDH1A1KDM4EPKMDNM1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4223309-A1 COMBINATION THERAPY WITH CONTROLLED-RELEASE CNP AGONISTS Ascendis Pharma Growth Disorders A/S (DK) 2023-08-09 EP disclosed
EP-3518930-B1 COMBINATION THERAPY WITH CONTROLLED-RELEASE CNP AGONISTS ASCENDIS PHARMA GROWTH DISORDERS AS (DK) 2023-03-08 EP disclosed